The death rate from cancer in the United States has fallen by more than one-third since 1991. HIV-related mortality has dropped ninefold since 1995. Death rates for Alzheimer's, chronic respiratory ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
Operator: Greetings, and welcome to the PDS Biotech First Quarter 2026 Earnings Conference Call. [Operator Instructions] It ...
Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination ...
Zacks Investment Research on MSN
Will Keytruda continue to aid MRK's growth in 2026 after a strong Q1?
Merck’s MRK strong oncology sales growth is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...
2d
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients
Dr. Kirk Shepard (Chief Medical Officer) detailed a pivotal change to the Phase III VERSATILE-003 study design: “we adopted an amendment to our VERSATILE-003 trial, revising the design to incorporate ...
On March 20, the FDA approved Opdivo for adult and pediatric patients (aged 12 years and older) with previously untreated ...
After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of ...
Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our ...
Following the paper trail to Guatemala to uncover what records can’t reveal about access to Keytruda
I had read countless legal documents about the world's bestselling drug. But it took a trip to Latin America to see how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results